phosphorylcholine has been researched along with Trypanosomiasis, African in 4 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Trypanosomiasis, African: A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papagiannaros, A | 1 |
| Bories, C | 1 |
| Demetzos, C | 1 |
| Loiseau, PM | 1 |
| Rose, LM | 1 |
| Goldman, M | 1 |
| Lambert, PH | 1 |
| Croft, SL | 1 |
| Snowdon, D | 1 |
| Yardley, V | 1 |
| Konstantinov, SM | 1 |
| Kaminsky, R | 1 |
| Brun, R | 1 |
| Berger, MR | 1 |
| Zillmann, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
4 other studies available for phosphorylcholine and Trypanosomiasis, African
| Article | Year |
|---|---|
Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Topics: Amines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug | 2005 |
Simultaneous induction of an idiotype, corresponding anti-idiotypic antibodies, and immune complexes during African trypanosomiasis in mice.
Topics: Animals; Antibody-Producing Cells; Antigen-Antibody Complex; B-Lymphocytes; Binding Sites, Antibody; | 1982 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Lei | 1996 |
Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Synergism; Drug Therap | 1997 |